Caprock Group LLC Takes $757,000 Position in ICU Medical, Inc. $ICUI

Caprock Group LLC purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 5,933 shares of the medical instruments supplier’s stock, valued at approximately $757,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. Inscription Capital LLC increased its position in shares of ICU Medical by 407.9% in the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock worth $1,003,000 after purchasing an additional 6,718 shares during the period. Bryce Point Capital LLC acquired a new stake in ICU Medical during the third quarter worth about $586,000. Federated Hermes Inc. increased its holdings in ICU Medical by 56.5% in the 3rd quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock valued at $34,823,000 after buying an additional 104,798 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new position in shares of ICU Medical in the 3rd quarter valued at approximately $1,096,000. Finally, AlphaQuest LLC lifted its holdings in shares of ICU Medical by 3,058.3% during the 2nd quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock worth $200,000 after acquiring an additional 1,468 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ICUI has been the subject of several research analyst reports. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Piper Sandler raised their price objective on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, KeyCorp lifted their target price on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.67.

ICU Medical Price Performance

ICU Medical stock opened at $144.90 on Tuesday. The firm has a market capitalization of $3.58 billion, a P/E ratio of -467.40 and a beta of 0.79. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $165.17. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. The business has a fifty day moving average price of $148.98 and a 200-day moving average price of $135.33.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.